Frontline and Sinopharm to Invest in China Life Science Together

Frontline BioVentures, a Shanghai-based VC firm specializing in China life science companies, announced it has led a Series A round of unspecified size for Sino Health, a Sinopharm company. Last year, Sino Health brought in strategic investors and sold off its nutritional food business to become an investment vehicle for a group that includes the state-owned Sinopharm, China's largest pharma. Frontline, together with other new investors, now joins that group and promises to use its contacts to provide Sino Health with a pipeline of innovative products and cutting edge technologies. Sinopharm will distribute the products. More details.... Share this with colleagues: // //